erlotinib hydrochloride has been researched along with Epithelial Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anile, M; Bellissimo, T; Blandino, G; De Angelis, L; Diso, D; Facciolo, F; Fazi, F; Gallo, E; Ganci, F; Giangaspero, F; Marino, M; Masciarelli, S; Pescarmona, E; Petrozza, V; Pulito, C; Sacconi, A; Tito, C; Venuta, F | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Dean, E; Hamilton, M; Judson, I; McCarthy, S; Ranson, M; Reid, A; Shaw, H; Wolf, J | 1 |
| Balko, JM; Black, EP; Britson, J; Bryant, JL; Frolov, A; Timmons, R; Willian, M | 1 |
| Gui, T; Shen, K | 1 |
| Blank, SV; Chang, R; Muggia, F | 1 |
3 review(s) available for erlotinib hydrochloride and Epithelial Neoplasms
| Article | Year |
|---|---|
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
2 trial(s) available for erlotinib hydrochloride and Epithelial Neoplasms
| Article | Year |
|---|---|
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines | 2010 |
2 other study(ies) available for erlotinib hydrochloride and Epithelial Neoplasms
| Article | Year |
|---|---|
Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epigenesis, Genetic; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasms, Glandular and Epithelial; RNA, Messenger; Thymoma; Thymus Neoplasms | 2017 |
A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Quinazolines | 2012 |